MX2020012596A - Procesos e intermedios para preparar un medicamento. - Google Patents
Procesos e intermedios para preparar un medicamento.Info
- Publication number
- MX2020012596A MX2020012596A MX2020012596A MX2020012596A MX2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A MX 2020012596 A MX2020012596 A MX 2020012596A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- intermediates
- processes
- medicament
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Se divulga un proceso para preparar los siguientes compuestos: (ver Fórmulas) en donde R1, R1a y R2a son como se han definido en la memoria descriptiva, así como también un proceso para preparar otros intermedios que pueden ser útiles para sintetizar productos posteriores, especialmente compuestos que son útiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib; también se divulgan otros procesos, otros intermedios y compuestos per se.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361786842P | 2013-03-15 | 2013-03-15 | |
EP13159470 | 2013-03-15 | ||
EP13197813 | 2013-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020012596A true MX2020012596A (es) | 2021-02-09 |
Family
ID=51535892
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012731A MX2015012731A (es) | 2013-03-15 | 2014-03-11 | Procesos e intermedios para preparar un medicamento. |
MX2020012596A MX2020012596A (es) | 2013-03-15 | 2015-09-14 | Procesos e intermedios para preparar un medicamento. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012731A MX2015012731A (es) | 2013-03-15 | 2014-03-11 | Procesos e intermedios para preparar un medicamento. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2970291B1 (es) |
JP (1) | JP6777398B2 (es) |
KR (2) | KR102377688B1 (es) |
CN (2) | CN105026400A (es) |
AU (2) | AU2014230935A1 (es) |
BR (1) | BR112015021856A2 (es) |
CA (1) | CA2901510C (es) |
DK (1) | DK2970291T3 (es) |
EA (1) | EA201591685A1 (es) |
ES (1) | ES2924193T3 (es) |
HR (1) | HRP20220628T1 (es) |
HU (1) | HUE058914T2 (es) |
LT (1) | LT2970291T (es) |
MX (2) | MX2015012731A (es) |
MY (1) | MY194905A (es) |
PE (1) | PE20151652A1 (es) |
SG (2) | SG10201809696UA (es) |
SI (1) | SI2970291T1 (es) |
WO (1) | WO2014139970A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014004971B1 (pt) | 2011-09-02 | 2021-02-09 | Incyte Holdings Corporation | compostos heterociclilaminas, sua composição farmacêutica e seus usos |
CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
CN104447761A (zh) * | 2014-11-27 | 2015-03-25 | 广东东阳光药业有限公司 | 一种吡唑衍生物的制备方法 |
EP3248979B1 (en) * | 2015-01-21 | 2021-04-14 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | Novel inhibitor of flt3 kinase and use thereof |
CN105481862B (zh) * | 2015-01-21 | 2018-08-21 | 中国科学院合肥物质科学研究院 | Flt3激酶的新型抑制剂及其用途 |
SI3831833T1 (sl) * | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
LV15201B (lv) * | 2015-08-31 | 2017-07-20 | Latvijas Organiskās Sintēzes Institūts | Ibrutiniba izejvielas iegūšanas paņēmiens |
CN106608877B (zh) * | 2015-10-21 | 2018-11-13 | 新发药业有限公司 | 一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法 |
JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
WO2018103058A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
WO2018145280A1 (zh) * | 2017-02-09 | 2018-08-16 | 合肥合源药业有限公司 | Flt3激酶抑制剂或其盐的晶型及其制备方法 |
CN107383017B (zh) * | 2017-07-20 | 2020-01-14 | 河南师范大学 | 依鲁替尼高效制备方法 |
EP3661939B1 (en) * | 2017-08-01 | 2021-07-21 | Boehringer Ingelheim International GmbH | Intermediate compounds and methods |
MX2021014245A (es) | 2019-05-21 | 2022-01-06 | Janssen Pharmaceutica Nv | Procedimientos y productos intermedios para preparar un inhibidor de btk. |
KR20220011668A (ko) | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
CN113200987A (zh) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | 一种伊布替尼的制备方法 |
CN115322226B (zh) * | 2022-08-17 | 2023-08-11 | 厦门大学 | 一种共价靶向砷抑制剂及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1212327T3 (da) * | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
KR101315610B1 (ko) * | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
CA2668286C (en) * | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
CA2874756C (en) * | 2007-03-28 | 2018-05-29 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
SI2414363T1 (sl) | 2009-03-31 | 2014-04-30 | Boehringer Ingelheim Gmbh | Derivati 1-heterociklil-1,5-dihidro-pirazolo/3,4-d/pirimidin-4-ona in njihova uporaba kot modulatorji za PDE9A |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
AU2011276955B2 (en) * | 2010-07-09 | 2014-11-06 | The Walter And Eliza Hall Institute Of Medical Research | Protein kinase inhibitors and methods of treatment |
EP2632898A4 (en) * | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
KR20140048968A (ko) * | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
EP2882741B1 (en) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
US20150291554A1 (en) * | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
-
2014
- 2014-03-11 MY MYPI2015002280A patent/MY194905A/en unknown
- 2014-03-11 PE PE2015001956A patent/PE20151652A1/es unknown
- 2014-03-11 KR KR1020217031854A patent/KR102377688B1/ko active IP Right Grant
- 2014-03-11 HR HRP20220628TT patent/HRP20220628T1/hr unknown
- 2014-03-11 HU HUE14708885A patent/HUE058914T2/hu unknown
- 2014-03-11 ES ES14708885T patent/ES2924193T3/es active Active
- 2014-03-11 CA CA2901510A patent/CA2901510C/en active Active
- 2014-03-11 CN CN201480015131.5A patent/CN105026400A/zh active Pending
- 2014-03-11 JP JP2015562078A patent/JP6777398B2/ja active Active
- 2014-03-11 SI SI201431956T patent/SI2970291T1/sl unknown
- 2014-03-11 KR KR1020157025525A patent/KR102311329B1/ko active IP Right Grant
- 2014-03-11 LT LTEPPCT/EP2014/054621T patent/LT2970291T/lt unknown
- 2014-03-11 SG SG10201809696UA patent/SG10201809696UA/en unknown
- 2014-03-11 SG SG11201507595XA patent/SG11201507595XA/en unknown
- 2014-03-11 DK DK14708885.0T patent/DK2970291T3/da active
- 2014-03-11 EP EP14708885.0A patent/EP2970291B1/en active Active
- 2014-03-11 EA EA201591685A patent/EA201591685A1/ru unknown
- 2014-03-11 AU AU2014230935A patent/AU2014230935A1/en not_active Abandoned
- 2014-03-11 WO PCT/EP2014/054621 patent/WO2014139970A1/en active Application Filing
- 2014-03-11 CN CN202011305518.8A patent/CN112608298A/zh active Pending
- 2014-03-11 MX MX2015012731A patent/MX2015012731A/es unknown
- 2014-03-11 BR BR112015021856A patent/BR112015021856A2/pt not_active Application Discontinuation
-
2015
- 2015-09-14 MX MX2020012596A patent/MX2020012596A/es unknown
-
2018
- 2018-06-08 AU AU2018204086A patent/AU2018204086B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016510779A (ja) | 2016-04-11 |
KR20210123429A (ko) | 2021-10-13 |
LT2970291T (lt) | 2022-06-10 |
MX2015012731A (es) | 2016-02-18 |
HUE058914T2 (hu) | 2022-09-28 |
CN112608298A (zh) | 2021-04-06 |
AU2018204086A1 (en) | 2018-06-28 |
CN105026400A (zh) | 2015-11-04 |
EA201591685A1 (ru) | 2016-01-29 |
WO2014139970A1 (en) | 2014-09-18 |
AU2018204086B2 (en) | 2020-03-12 |
MY194905A (en) | 2022-12-22 |
PE20151652A1 (es) | 2015-11-12 |
BR112015021856A2 (pt) | 2017-07-18 |
JP6777398B2 (ja) | 2020-10-28 |
AU2014230935A1 (en) | 2015-09-03 |
DK2970291T3 (da) | 2022-08-01 |
KR102377688B1 (ko) | 2022-03-22 |
EP2970291A1 (en) | 2016-01-20 |
KR102311329B1 (ko) | 2021-10-14 |
EP2970291B1 (en) | 2022-05-11 |
SI2970291T1 (sl) | 2022-07-29 |
SG11201507595XA (en) | 2015-10-29 |
KR20150132172A (ko) | 2015-11-25 |
CA2901510A1 (en) | 2014-09-18 |
ES2924193T3 (es) | 2022-10-05 |
CA2901510C (en) | 2022-11-29 |
HRP20220628T1 (hr) | 2022-06-24 |
SG10201809696UA (en) | 2018-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020012596A (es) | Procesos e intermedios para preparar un medicamento. | |
MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
PH12017500166A1 (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
TN2014000427A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
MX2016003582A (es) | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. | |
MD20150048A2 (ro) | Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K | |
MX357305B (es) | Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1. | |
EA030383B9 (ru) | Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением | |
MY173877A (en) | Branched 3-phenylpropionic acid derivatives and the use thereof | |
MX336214B (es) | Derivados de pirrolotriazinona como inhibidores de pi3k. | |
MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
MX2015010354A (es) | Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih). | |
MY175804A (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
NZ719169A (en) | Heteroaryl butanoic acid derivatives as lta4h inhibitors | |
MX2016000794A (es) | Composiciones farmaceuticas de pancreatina de potencia alta. | |
MX2015012343A (es) | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa. | |
TN2015000095A1 (en) | Macrolide derivatives, preparation thereof and therapeutic use thereof | |
PH12015502000A1 (en) | Processes and intermediates for preparing a medicament | |
IN2013CH04314A (es) | ||
IN2013MU02059A (es) | ||
TN2013000243A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof |